- Report
- August 2023
Switzerland
From €1633EUR$1,850USD£1,423GBP
- Report
- August 2023
Pakistan
From €1633EUR$1,850USD£1,423GBP
- Report
- August 2023
Japan, United States, ... Japan, United States, Europe, Global
From €12797EUR$14,500USD£11,154GBP
- Report
- August 2023
Canada, Mexico, North America Canada, Mexico, North America
From €8384EUR$9,500USD£7,308GBP
- Report
- August 2023
Middle East
From €8384EUR$9,500USD£7,308GBP
- Report
- August 2023
Latin America
From €8384EUR$9,500USD£7,308GBP
- Report
- August 2023
Europe
From €12797EUR$14,500USD£11,154GBP
- Report
- August 2023
Asia Pacific
From €8384EUR$9,500USD£7,308GBP
- Report
- August 2023
Global
From €24270EUR$27,500USD£21,154GBP
- Report
- November 2025
- 132 Pages
Global
From €838EUR$950USD£731GBP
- Report
- March 2024
- 132 Pages
Global
From €838EUR$950USD£731GBP
The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more